

**Shih-Hsien Chuang, Ph.D.**

Dr. Chuang received his PhD degree in Medicinal Chemistry from National Tsing Hua University in 2005. He joined DCB and started his career in drug discovery since 2006. As a principal investigator in institute of pharmaceuticals, Dr. Chuang led several drug discovery projects especially on oncology field. For example, the Nek2/Hec1 inhibitor against advanced refractory solid tumors collaborated with Taivex Therapeutics was in Phase I clinical trial. Besides, Dr. Chuang also focused on developing novel technology platforms such as next generation antibody-drug conjugates (ADC) and proteolysis targeting chimera (PROTAC). Dr. Chuang had over 20 papers published in peer-reviewed journals.